News Releases

Date Title and Summary View
Apr 27, 2020
Apr 24, 2020
Apr 23, 2020
Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally
Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment First in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19 NEW BRUNSWICK, N.J.
Apr 21, 2020
Apr 14, 2020
Johnson & Johnson Reports 2020 First-Quarter Results
- Sales of $20.7 billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic - EPS of $2.17 increased 56.1%; adjusted EPS of $ 2.30 increased 9.5%* - Dividend increase of
Apr 14, 2020
Johnson & Johnson Announces Dividend Increase of 6.3%
NEW BRUNSWICK, N.J. , April 14, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share.  "In recognition of our 2019 results, strong financial position and
Apr 06, 2020
Apr 01, 2020
Johnson & Johnson Postpones 2020 Medical Devices Business Review Due to the Coronavirus
NEW BRUNSWICK, N.J. , April 1, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that, in light of the evolving situation with the coronavirus outbreak (COVID-19), it will reschedule its 2020 Medical Devices Business Review that was planned to take place on May 13, 2020 .  Johnson
Mar 31, 2020
Johnson & Johnson to Host Virtual Annual Meeting of Shareholders
NEW BRUNSWICK, N.J. , March 31, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the 2020 Annual Meeting of Shareholders will now be conducted exclusively online by remote communication. This decision was made in light of the coronavirus outbreak ("COVID-19"), public health
Mar 30, 2020
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson Will Establish New U.S.
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.